CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced it will present at the Morgan Stanley 23rd Annual Global Health Care Conference on Monday, September 8, 2025, at 7:45 a.m. EDT.
The presentation will be webcast live, with a replay available afterward through the company’s investor relations site.
Madrigal specializes in treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. Its lead therapy, Rezdiffra (resmetirom), is the first FDA- and European Commission-approved medication for MASH with moderate to advanced fibrosis. The company is also conducting a Phase 3 trial evaluating the drug in patients with compensated MASH cirrhosis.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.